TTX-MC138 Shows Survival Benefit in Breast Cancer

BOSTON, Aug. 31, 2026

TTX-MC138 Targets miR-10b in Bone Metastases

The published study, titled “Targeting miR-10b in Breast Cancer Bone Colonization Model Using Image-Guided Nucleic Acid-Based Therapeutics,” investigated the ability of TTX-MC138 to reach metastatic bone lesions following systemic administration. In the mouse model, the therapeutic successfully accumulated at sites of metastatic bone disease and reduced expression of miR-10b, while increasing expression of HOXD10, a downstream tumor-suppressor target. These molecular changes support the proposed mechanism of action in which inhibition of miR-10b may interfere with biological processes involved in metastatic progression. Importantly, animals receiving the anti-miR-10b therapeutic demonstrated a significant survival benefit compared with control animals. The study also reported that repeated dosing was well tolerated, with no observed evidence of systemic toxicity during the experimental period. These findings are particularly relevant because bone metastasis represents a major challenge in advanced breast cancer and is associated with substantial morbidity and poor long-term outcomes.

Preclinical Findings Support Metastatic Cancer Strategy

According to the researchers, the results support the potential use of image-guided anti-miR-10b nanotherapeutics as a translatable approach for metastatic cancer. The study was led by Dr. Anna Moore of Michigan State University’s College of Human Medicine, who is also a co-founder of TransCode Therapeutics and chair of the company’s Scientific Advisory Board. The research contributes to evidence that miR-10b inhibition could have therapeutic relevance across multiple metastatic tumor types. The publication also provides additional context for TransCode’s broader clinical development program. The company’s current TTX-MC138 clinical efforts are focused on metastatic cancers, including an ongoing program in molecular residual disease-positive colorectal cancer. TransCode reported that its Phase 1a first-in-human study of TTX-MC138 achieved its primary safety endpoint and established a recommended Phase 2 dose, although the newly reported breast cancer bone metastasis findings remain preclinical and should not be interpreted as evidence of clinical efficacy in patients. TTX-MC138 is described by TransCode as a first-in-class investigational therapeutic candidate designed to inhibit miR-10b, which the company identifies as an important biomarker associated with metastatic disease. The company is developing RNA-based and immuno-oncology approaches for advanced cancers. The latest publication strengthens the scientific rationale for investigating miR-10b inhibition in additional metastatic settings, while further clinical studies will be required to determine whether the preclinical findings translate into meaningful benefits for patients.

Source: TransCode Therapeutics press relese